# Study of Azacitidine and Durvalumab in Advanced Solid Tumors

> **NCT02811497** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 28 (actual)

## Conditions studied

- Microsatellite Stable Colorectal Carcinoma
- Platinum Resistant Epithelial Ovarian Cancer Type II
- Estrogen Receptor Positive and HER2 Negative Breast Cancer

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT02811497
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2018-11-08
- **Final completion:** 2020-08-04
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2021-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02811497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02811497, "Study of Azacitidine and Durvalumab in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02811497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*